Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness worldwide. Primary open-angle glaucoma is the most common form, and yet the etiology of this multifactorial disease is poorly understood. We aimed to identify plasma metabolites associated with the risk of developing POAG in a case-control study (599 cases and 599 matched controls) nested within the Nurses' Health Studies, and Health Professionals' Follow-Up Study. Plasma metabolites were measured with LC-MS/MS at the Broad Institute (Cambridge, MA, USA); 369 metabolites from 18 metabolite classes passed quality control analyses. For comparison, in a cross-sectional study in the UK Biobank, 168 metabolites were measured in plasma samples from 2,238 prevalent glaucoma cases and 44,723 controls using NMR spectroscopy (Nightingale, Finland; version 2020). Here we show higher levels of diglycerides and triglycerides are adversely associated with glaucoma in all four cohorts, suggesting that they play an important role in glaucoma pathogenesis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199010 | PMC |
| http://dx.doi.org/10.1038/s41467-023-38466-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Electrophysiological methods in the diagnosis and monitoring of glaucoma].
Vestn Oftalmol
September 2025
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Primary open-angle glaucoma (POAG) is characterized by chronic progressive damage to the retinal ganglion cell layer (GCL) and their axons, leading to gradual visual function loss. Currently, the gold standards for structural and functional assessment of the retina in glaucoma are static automated perimetry (SAP) and optical coherence tomography (OCT). However, in clinical practice, data from SAP and OCT may be insufficient to reliably determine the stage of glaucomatous optic neuropathy, monitor its progression, or differentiate it from other causes of visual dysfunction.
View Article and Find Full Text PDF[The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma].
Vestn Oftalmol
September 2025
OOO Diagnosticheskij tsentr Zreniye, Saint Petersburg, Russia.
Objective: This study evaluated the effect of sequential therapy with different dosages of Mexidol on the stabilization of glaucomatous optic neuropathy (GON) in patients with primary open-angle glaucoma (POAG).
Material And Methods: The study included 80 patients (160 eyes) with stage II and III POAG, randomized into three groups comparable by age, gender, and distribution of glaucoma stage. All patients received sequential therapy with Mexidol (14 days parenterally followed by 90 days orally).
Broad-spectrum therapeutic potential of 4-phenylbutyrate in neurological and systemic diseases of viral and non-viral origin.
Front Pharmacol
August 2025
Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL, United States.
4-Phenylbutyrate (4-PBA), initially recognized for treating urea cycle disorders, has emerged as a potent therapeutic agent with broad-spectrum potential. As a chemical chaperone, 4-PBA modulates protein folding and reduces endoplasmic reticulum stress. 4-PBA has demonstrated efficacy in treating ocular herpes simplex virus type 1 (HSV-1) infection and HSV-1-induced encephalitis, highlighting its potential as a novel anti-herpetic therapy.
View Article and Find Full Text PDFImpact of prostaglandin-associated periorbitopathy on surgical outcomes of trabeculectomy and ahmed glaucoma valve implantation.
Graefes Arch Clin Exp Ophthalmol
September 2025
Department of Ophthalmology, Shimane University Faculty of Medicine, Shimane, Japan.
Purpose: To evaluate the impact of prostaglandin-associated periorbitopathy (PAP) severity on the surgical outcomes of trabeculectomy (LEC) and Ahmed Glaucoma Valve (AGV) implantation in patients with primary open-angle glaucoma.
Methods: In this propensity score-matched retrospective cohort study, a total of 106 eyes with uncontrolled glaucoma were included. Postoperative follow-ups were conducted at 1, 3, 6, 9, and 12 months.
Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma:5-Year Safety Results from a Randomized, Multicenter Study.
Ophthalmol Glaucoma
September 2025
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, England; Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South Wales, Australia.
Purpose: To compare the long-term safety of MicroShunt implantation with trabeculectomy in eyes with primary open-angle glaucoma (POAG).
Methods: This was a 3-year observational extension of a 2-year prospective randomized trial comparing clinical outcomes of MicroShunt implantation with trabeculectomy, both augmented with mitomycin C. Adverse events (AEs), intraocular pressure (IOP), and IOP-lowering medication use were recorded 36, 48, and 60 months after initial randomization.